Brain arteriovenous malformations (bAVMs) are rare congenital lesions that confer a lifelong risk for hemorrhage. Treatment options for these lesions include microsurgical resection, embolization, and radiosurgery, alone or in combination. The goal of bAVM intervention is to eliminate the risk for future hemorrhage, which must mean complete obliteration of the lesion.
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However, treatment also poses a risk for morbidity and morbidity.
Two recent high-profile studies compared outcomes between patients with bAVMs treated with multimodality therapy with those managed conservatively. 1, 2 Although both studies on the surface demonstrate worse outcome following intervention, they both have significant limitations, which preclude the conclusion that conservative management is superior to intervention in patients with bAVMs.
The primary results of the Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA) trial were recently published. 1 This multicentered international randomized trial compared interventional treatment to medical management for unruptured bAVMs. The primary endpoint of the study was symptomatic stroke or death, with a secondary outcome of death and disability measured by the modified Rankin scale (mRS). The trial was initially designed to include 800 patients, however, the target sample size was later reduced to 400 and the trial was halted after only 223 subjects were randomized. Of the 109 patients in the medical group, This study also suffers from several weaknesses that limit conclusions that can be drawn from the data. First, this was a nonrandomized study, and thus there are inherent differences between cohorts. Next, the authors report a complication rate of 27.1 % in the intervention group. This is strikingly high relative to the rate of 5.7 % calculated in a recent meta-analysis of 13,698 bAVM patients. 4 Additionally, the authors report a bAVM obliteration rate of only 66 %, which must be judged against a surgical obliteration rate of 96 % in the meta-analysis. Finally, 20 of 31 deaths in the conservative group were classified as unrelated to the AVM, which represents a much higher rate than in the treated cohort (six of 10).
Mortality from AVM rupture occurring in patients who did not make it to the hospital may clearly have been missed.
Given the significant limitations of both of these recently published studies, it is impossible to conclude that conservative management will result in better outcomes than intervention for the broad population of unruptured bAVMs. Furthermore, neither of these studies can be effectively extrapolated to centers that routinely employ surgical resection of low-grade bAVMs. Further work is therefore necessary, and the establishment of a multicenter, adjudicated registry of consecutive patients is warranted. n
